Trazodone Dosage

This dosage information may not include all the information needed to use Trazodone safely and effectively. See additional information for Trazodone.

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Geriatric Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Depression

Immediate-release tablets:
Initial dose: 150 mg per day in divided doses.
Maintenance dose: May be increased by 50 mg per day every 3 to 4 days. The maximum dose for outpatients usually should not exceed 400 mg per day in divided doses. Inpatients may be given up to but not in excess of 600 mg per day in divided doses.
Trazodone should be taken shortly after a meal or light snack.

Extended-release tablets:
Recommended starting dose: 150 mg once daily
Maintenance dose: The dose may be increased by 75 mg/day every three days (for example, start 225 mg on day 4 of therapy).
Maximum daily dose: 375 mg
Trazodone extended-release tablets should be taken orally at the same time every day, in the late evening preferably at bedtime, on an empty stomach. Once an adequate response has been achieved, dosage may be gradually reduced, with subsequent adjustment depending on therapeutic response.

Patients should be monitored for withdrawal symptoms when discontinuing treatment with trazodone hydrochloride. The dose should be gradually reduced whenever possible.

The efficacy of trazodone extended-release tablets for the maintenance treatment of MDD has not been evaluated. While there is no body of evidence available to answer the question of how long a patient treated with trazodone extended-release tablets should continue the drug, it is generally recommended that treatment be continued for several months after an initial response. Patients should be maintained on the lowest effective dose and be periodically reassessed to determine the continued need for maintenance treatment.

Usual Geriatric Dose for Depression

Immediate-release tablets:
Initial dose: 150 mg per day in divided doses.
Maintenance dose: May be increased by 50 mg per day every 3 to 4 days. The maximum dose for outpatients usually should not exceed 400 mg per day in divided doses. Inpatients may be given up to but not in excess of 600 mg per day in divided doses.
Trazodone should be taken shortly after a meal or light snack.

Extended-release tablets:
Recommended starting dose: 150 mg once daily
Maintenance dose: The dose may be increased by 75 mg/day every three days (for example, start 225 mg on day 4 of therapy).
Maximum daily dose: 375 mg
Trazodone extended-release tablets should be taken orally at the same time every day, in the late evening preferably at bedtime, on an empty stomach. Once an adequate response has been achieved, dosage may be gradually reduced, with subsequent adjustment depending on therapeutic response.

Patients should be monitored for withdrawal symptoms when discontinuing treatment with trazodone hydrochloride. The dose should be gradually reduced whenever possible.

The efficacy of trazodone extended-release tablets for the maintenance treatment of MDD has not been evaluated. While there is no body of evidence available to answer the question of how long a patient treated with trazodone extended-release tablets should continue the drug, it is generally recommended that treatment be continued for several months after an initial response. Patients should be maintained on the lowest effective dose and be periodically reassessed to determine the continued need for maintenance treatment.

In the clinical trial, there were nine patients older than 65. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical literature and experience with trazodone have not identified differences in responses between elderly and younger patients. However, as experience in the elderly with trazodone extended-release tablets is limited, it should be used with caution in geriatric patients.

Antidepressants have been associated with cases of clinically significant hyponatremia in elderly patients who may be at greater risk for this adverse reaction.

Usual Pediatric Dose for Depression

(Not approved by FDA)
Immediate-release tablets:
6 to 12 years:
Initial dose: 1.5 to 2 mg/kg/day in divided doses.
Maintenance dose: May increase up to 6 mg/kg/day in 3 divided doses.

Greater than 12 years to 18 years:
Initial dose: 25 to 50 mg per day.
Maintenance dose: May increase up to 100 to 150 mg per day in divided doses.

Trazodone should be taken shortly after a meal or light snack.

Renal Dose Adjustments

Because the metabolites of trazodone are eliminated by the kidneys, and at least one such metabolite may be active, use of trazodone is not recommended for use in patients with renal dysfunction.

Liver Dose Adjustments

The disposition and safety of trazodone in patients with liver dysfunction has not been described. Therefore, if trazodone must be used, it should be used very cautiously. Consideration should be given to the use of alternative therapies in patients with liver dysfunction.

Dose Adjustments

Occurrence of drowsiness may require the administration of a major portion of the daily dose at bedtime or a reduction of dosage. Once an adequate response has been achieved, dosage may be gradually reduced, with subsequent adjustment depending on therapeutic response.

Precautions

The use of MAOIs intended to treat psychiatric disorders (and other MAOIs such as linezolid and intravenous methylene blue) with trazodone or within 14 days of stopping treatment with trazodone is contraindicated due to an increase in the risk of serotonin syndrome. The use of trazodone within 14 days of stopping an MAOI intended to treat psychiatric disorders (and other MAOIs such as linezolid and intravenous methylene blue) is also contraindicated.

Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).

Dialysis

Because the metabolites of trazodone are eliminated by the kidneys, and at least one such metabolite may be active, use of trazodone is not recommended for use in patients with renal dysfunction.

Other Comments

Symptomatic relief may be seen during the first week, with optimal antidepressant effects typically evident within 2 weeks.

Trazodone extended-release tablets are scored to provide flexibility in dosing. Trazodone extended-release tablets can be swallowed whole or administered as a half tablet by breaking the tablet along the score line. Breaking the tablet in half does not affect the controlled-release properties of the tablet.

In order to maintain its controlled-release properties, trazodone extended-release tablets should not be chewed or crushed.

Hide
(web4)